Establishment of clinical basis for hematopoietic growth factors therapy in brain injury

Yonsei University Health System, Severance Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年8月1日

适应症

试验速览

暂无简介。

•In terms of subject selection criteria, the following conditions apply: 1) Adults aged 19 and above who are capable of providing voluntary consent, 2) Individuals with brain injuries occurring after the acute phase (one week after brain injury) such as ischemic brain injury, hypoxic-ischemic brain injury, hemorrhagic brain injury 3) Individuals who, according to the attending physician, are clinically eligible for re-enrollment in the study at least 6 months after the last hematopoietic growth factor injection.

•The exclusion criteria for the subjects are as follows: 1) Individuals under the age of 19 who are incapable of providing voluntary consent, 2) Presence of cerebral lesions such as tumors or infections, 3) Use of anticoagulant warfarin (coumadin) (excluding medications from the antiplatelet drug class), 4) Leukopenia, thrombocytopenia, polycythemia, 5) History of malignant disease or myeloproliferative disorders, 6) Septic embolism, malignant hypertension, hyperkalemia, 7) Hepatic or renal dysfunction; serum creatinine > 3 mg/dl, 8) Allergy to erythropoietin or G-CSF medications, 9) Exclusion criteria for MRI examination, 10) Pregnant or breastfeeding women, 11) Body temperature above 38 degrees Celsius, presence of pneumonia on chest radiography, 12) Recurrent pneumonia symptoms, 13) Blood pressure exceeding 140/90 mmHg despite the use of antihypertensive medications, 14) Hemoglobin levels exceeding 15 g/dL. Individuals meeting any of these criteria will be excluded from the target group.

发起方